Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

Group 1: Investment and Fundraising - Hanyu Pharmaceutical plans to raise no more than 968 million yuan for the development of semaglutide and other projects [1] - Ganfeng Lithium intends to introduce investors for a capital increase of up to 2.5 billion yuan [9] Group 2: Strategic Restructuring - Pingmei Shenma Holdings is undergoing a strategic restructuring as directed by the Henan provincial government, which will not affect the company's operations significantly [2][8] - Shennong Holdings is also involved in a strategic restructuring with no change in control or significant impact on operations [7][8] Group 3: Clinical Trials and Approvals - XinNuoWei's subsidiary received approval for clinical trials of a drug for treating mild Alzheimer's disease, marking a significant milestone in the development of biosimilar drugs [3] - Tainkang's subsidiary has received approval for clinical trials of CKBA cream for rosacea, a first-class innovative drug in China [4] - Baili Tianheng's drug, iza-bren, has been included in the list of breakthrough therapies, indicating its potential in treating advanced urinary tract cancer [5] Group 4: Contracts and Projects - Zhongyou Engineering signed an EPC contract worth 2.524 billion USD for a seawater pipeline project in Iraq, expected to positively impact future revenues [6]

Core Viewpoint - On September 25, no A-share listed companies disclosed any increase in shareholding, while 16 companies announced share reductions, indicating a trend of shareholder divestment in the market [1]. Summary by Category Share Reduction Details - Hanghua Co. plans to reduce up to 4.24 million shares of repurchased stock to supplement working capital [2] - Weili Sealing's shareholders plan to reduce up to 1% of the company's shares [2] - Milkewei's actual controller and shareholders intend to collectively reduce up to 4.02% of the company's shares [2] - Zhichun Technology's controlling shareholder reduced 4.2678 million shares on September 25 [2] - Xinao Micro's senior management plans to reduce up to 0.0134% of the company's shares [2] - Quanfeng Technology's Hesheng Health Insurance reduced 57.1419 million shares from September 22 to September 24 [2] - Morning Light Biological's senior management Li Fengfei plans to reduce up to 140,000 shares [2] - Everbright Jiabao's Jiading Jianye and Jiading Keti plan to reduce up to 1% of their shares [2] - Shengshi Technology's employee stock ownership platform plans to reduce up to 3% of the company's shares [2] - Xingsen Technology's actual controller Qiu Xingya reduced a total of 9.9639 million shares from August 5 to September 22 [2] - Haizheng Materials' Sinopec Capital plans to reduce up to 2.0267 million shares, accounting for 1% of the total share capital [2] - Zhengzhong Design's controlling shareholder plans to reduce up to 3% of the company's shares [2] - Baiya Co.'s three shareholders plan to collectively reduce up to 2% of the company's shares [2] - Jialiqi's shareholders plan to collectively reduce up to 3% of the company's shares [2] - Defu Technology's shareholders plan to collectively reduce up to 0.13% of the company's shares [2] - Jinyinhe's shareholders plan to reduce up to 0.35% of the company's total share capital [2] Market Signal - The MACD golden cross signal has formed, indicating a positive trend for certain stocks [1]

（编辑 任世碧） 证券日报网讯 9月25日晚间，杭华股份发布公告称，公司于2025年9月25日召开第四届董事会第十四次 会议，审议通过《关于回购股份集中竞价减持计划的议案》。根据公司于2024年2月8日在上海证券交易 所网站披露《杭华油墨股份有限公司关于以集中竞价交易方式回购公司股份的回购报告书》的有关要 求，为补充公司日常经营所需要的流动资金，公司计划自本公告披露之日起15个交易日后的3个月内， 通过集中竞价交易方式，按照市场价格累计减持不超过4，241，707股已回购股份，占公司总股本的 1%。 ...

Group 1 - The company, Hanghua Co., Ltd. (688571), announced on September 25 that it plans to reduce its holdings of repurchased shares by up to 4.2417 million shares, which represents 1% of the total share capital [1] - The reduction will occur through centralized bidding transactions within three months after 15 trading days [1] - The funds raised from this share reduction will be used to supplement the company's working capital for daily operations [1]

证券代码：688571 证券简称：杭华股份 公告编号：2025-049 杭华油墨股份有限公司 关于回购股份集中竞价减持计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 回购股份的基本情况 杭华油墨股份有限公司（以下简称"公司"或"杭华股份"）于 2024 年 2 月 6 日至 2024 年 4 月 30 日期间累计回购公司股份 7,563,368 股，占公司目前总 股本的 1.78%。前述回购的股份用于维护公司价值及股东权益，将在披露回购结 果暨股份变动公告 12 个月后采用集中竞价交易方式出售，并在披露回购结果暨 股份变动公告后 36 个月内完成出售，公司如未能在上述期限内完成出售，尚未 出售的已回购股份将予以注销。截至本公告披露日，公司尚未减持或转让前述股 份。 减持计划的主要内容 公司于 2025 年 9 月 25 日召开第四届董事会第十四次会议，审议通过《关于 回购股份集中竞价减持计划的议案》。根据《上海证券交易所上市公司自律监管 指引第 7 号——回购股份》的规定以及公司于 ...

杭华油墨股份有限公司 信息披露暂缓与豁免业务管理制度 杭华油墨股份有限公司 信息披露暂缓与豁免业务管理制度 第一章 总 则 第一条 为规范杭华油墨股份有限公司（以下简称"公司"）信息披露暂缓 与豁免行为，确保公司依法合规地履行信息披露义务，保护投资者的合法权益， 依据《中华人民共和国证券法》《上市公司信息披露管理办法》《上市公司信息 披露暂缓与豁免管理规定》《上海证券交易所科创板股票上市规则》（以下简称 "《上市规则》"）和《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等法律、法规、规范性文件的相关规定以及《杭华油墨股份有限公 司章程》（以下简称"《公司章程》"）以及《杭华油墨股份有限公司信息披露 制度》，制定本制度。 第二条 公司按照相关法律、法规、规范性文件、《上市规则》及上海证券 交易所（以下简称"上交所"）其他相关业务规则的规定，暂缓、豁免披露临时 报告，在定期报告、临时报告中豁免披露中国证券监督管理委员会（以下简称"中 国证监会"）和上交所规定或者要求披露的内容，适用本制度。 第三条 公司应当披露的信息存在《上市规则》及上交所其他相关业务规则 中规定的暂缓、豁免情形的，可以无须 ...

董事、高级管理人员离职管理制度 杭华油墨股份有限公司 董事、高级管理人员离职管理制度 杭华油墨股份有限公司 第一章 总则 第一条 为规范杭华油墨股份有限公司（以下简称"公司"）董事、高级管理 人员离职程序，保障公司治理稳定性及股东合法权益，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司章程指引》等法律、法规、规章和《杭华油墨股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，制定本制度。 董事提出辞任的，公司应当在六十日内完成补选，确保董事会构成符合法律、 行政法规、部门规章及《公司章程》的规定。 第四条 非职工代表董事由股东会选举和更换，职工代表董事由职工代表大 会选举和更换。非职工代表董事任期届满未获连任的，自股东会决议通过之日自 动离职。职工代表董事任期届满未获连任的，自相关职工代表大会决议通过之日 自动离职。 第五条 股东会可以决议解任董事（职工董事由职工代表大会解任），决议作 出之日解任生效。 无正当理由，在任期届满前解任董事、高级管理人员的，董事、高级管理人 员可以要求公司予以赔偿。公司应依据法律法规、《公司章程》 ...

杭华油墨股份有限公司 独立董事专门会议制度 杭华油墨股份有限公司 独立董事专门会议制度 第一条 为充分发挥独立董事在董事会中参与决策、监督制衡、专业咨询等职 能，进一步完善公司的治理结构，保护中小股东及利益相关者的利益，促进公司 的规范运作，根据《中华人民共和国公司法》《上市公司治理准则》《上市公司独 立董事管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》《杭华油墨股份有限公司章程》 （以下简称"《公司章程》"）等有关法律、法规和规范性文件的有关规定，并结 合公司实际情况，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及公司 主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行 独立客观判断关系的董事。 第三条 独立董事专门会议是指全部由公司独立董事参加的会议。独立董事 专门会议对所议事项进行独立研讨，从公司和中小股东利益角度进行思考判断， 并且形成讨论意见。 第四条 公司应当定期或者不定期召开全部由独立董事参加的会议。独立董 事专门会议原则上应当于召开前三天通知全体独立董事并提供相关资料和信息。 ...

杭华油墨股份有限公司 股东会议事规则 杭华油墨股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范杭华油墨股份有限公司（以下简称"公司"）行为，保证股 东会依法行使职权，根据《中华人民共和国公司法》（以下简称《公司法》）、《中 华人民共和国证券法》（以下简称《证券法》）、《上市公司股东会规则》等相关法 律、行政法规、规范性文件和《杭华油墨股份有限公司章程》（以下简称"《公司 章程》"）的规定，制定本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的六个月内举行。临时股东会不定期召开，出现《公 司法》第一百一十三条规定的应当召开临时股东会的情形时，临时股东会应当在 两个月内召开。 公司在上述期限内不能召开股东会的，应当报告公司所在地中国证券监督管 理委员会（以下简称"中国证监会"）派出机构和公司股票挂牌交易的证券交易 所（以下简称"证券交易所"），说明原因并公告。 1 / 13 杭华油墨股份有限公司 股东会议事规则 第六条 公司召开股东会的，应当聘请律师对以下问题出具法律意见并公 告： 第三 ...